Sun Pharma: An update on generic Eloxatin® injection

Mumbai, June 26, 2010: Sun Pharma Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) announced that the U.S. District Court for the District of New Jersey denied Sun Pharma’s motion to suspend the court's order dated April 22, 2010 which entered a Consent Judgement and Order having the effect of enjoining Sun Pharma from selling a generic oxaliplatin product.  Accordingly Sun Pharma will stop selling the product after June 30, 2010.

On April 30, 2010 Sun Pharma appealed the court order dated April 22, 2010 and intends to litigate the matter before the United States Court of Appeals for the Federal Circuit.  Sun Pharma believes that the grounds for appeal are strong and plans to contest the entry of the Consent Judgement and Order vigorously.  On receipt of a favorable judgement from the appellate court, SUN plans to reinitiate the sales of the product.

Eloxatin® is a registered trademark of sanofi aventis US LLC.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company.  It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.  In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics and ophthalmology.  The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.